The Lancet Haematology in conversation with

Marc Riedl on hereditary angioedema

Thu, 02 Apr 2026 10:00:00 +0100

Professor Marc Riedl joins us to discuss two trials testing oral deucrictibant for hereditary angioedema attacks: one testing deucrictibant as on-demand therapy to treat attacks and the other testing deucrictibant for prophylaxis of attacks.

Click here to read the full articles:

https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(25)00341-2/fulltext

https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(26)00004-9/fulltext

Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv

Julio Delgado and Valentín Ortiz-Maldonado (Spanish version)

Wed, 04 Mar 2026 23:00:00 +0000

Dr Julio Delgado and Dr Valentín Ortiz-Maldonado join us to discuss the results of their phase 2 trial testing varnimcabtagene autoleucel for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia in Spain.

Click here to read the full article:

https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(25)00328-X/fulltext

English version of this podcast:

https://www.buzzsprout.com/1564352/episodes/18730659

Julio Delgado and Valentín Ortiz-Maldonado

Wed, 04 Mar 2026 23:00:00 +0000

Click here to read the full article:

https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(25)00328-X/fulltext

Erica Kaye and Dylan Graetz discuss expert recommendations for the conduct and appraisal of qualitative research in haematology

Wed, 04 Feb 2026 23:00:00 +0000

Dr Erica Kaye and Dr Dylan Graetz join us to discuss the importance of qualitative research and how the whole research ecosystem can incorporate and support this type of research to help set the right research questions, and promote the patient voice.

Click here to read the full article: https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(25)00321-7/fulltext

Presented at ASH: API-CAT post-hoc analysis on predictors of clinically relevant bleeding during extended anticoagulation for cancer-associated VTE

Wed, 31 Dec 2025 23:00:00 +0000

Professor Isabelle Mahé joins us to discuss the results of a post-hoc analysis of the API-CAT trial identifying predictors associated with clinically relevant bleeding during extended anticoagulation for cancer-associated venous thromboembolism.

Click here to read the full article: https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(25)00291-1/fulltext

Presented at ASH 2025: EPCORE CLL-1 trial on epcoritamab monotherapy for Richter transformation

Mon, 08 Dec 2025 23:00:00 +0000

Arnon Kater joins Daniela Marin of The Lancet Haematology to discuss the phase 1b/2 EPCORE CLL-1 trial of epcoritamab monotherapy for Richter transformation, which is being presented at ASH 2025.

Click here to read the full article: https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(25)00327-8/fulltext

ASH 2025 Preview - Expert Roundtable

Tue, 02 Dec 2025 23:00:00 +0000

Khaled Musallam, Bethany Samuelson Bannow, Mohamad Mohty, David Sallman, and Anna Sureda join us to share their expectations for the upcoming ASH 2025 congress, to be held from 6 to 9 December 2025 in Orlando, on classical and malignant haematology.

Arnon Kater and Sabina Kersting on the HOVON 158/NEXT STEP phase 2 trial testing a new first-line treatment regimen for chronic lymphocytic leukaemia

Mon, 01 Dec 2025 23:00:00 +0000

Professor Arnon Kater and Dr Sabina Kersting join us to discuss the results of their phase 2 trial testing a new first-line treatment regimen in chronic lymphocytic leukaemia: fixed-duration ibrutinib–venetoclax followed by MRD-guided ibrutinib–obinutuzumab intensification.

Click here to read the full article: https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(25)00288-1/fulltext

Ruben Mesa on ropeginterferon alfa-2b for hydroxyurea-intolerant or hydroxyurea-refractory essential thrombocythaemia

Mon, 03 Nov 2025 11:00:00 +0000

Dr. Ruben Mesa (Executive Director of the Wake Forest Baptist Comprehensive Cancer Center) joins us to discuss the results of a multicentre, open-label, randomised, active-controlled, phase 3 study of ropeginterferon alfa-2b in hydroxyurea-intolerant or hydroxyurea-refractory essential thrombocythaemia.

Click here to read the full article

A panel of the authors on our Lancet Haematology-Lancet Regional Health Western Pacific Series on mature T-cell and natural killer-cell lymphomas

Sun, 14 Sep 2025 23:00:00 +0100

Today, on World Lymphoma Awareness Day, Professors Yok Lam Kwong, Wee Joo Chng, and Eric Tse join us in this joint episode of The Lancet Haematology and The Lancet Regional Health - Western Pacific to discuss their recent Series on advances in genomic techniques that have transformed the diagnosis, prognosis, and targeted treatment of mature T-cell and natural killer-cell lymphoma.

Read the Series:

https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(25)00228-5/?dgcid=buzzsprout_icw_podcast_September_25_lanhae

Lan-Lan Smith, Cheryl Lai, and Daniela Marín discuss the EHA, ICML, and ISTH conferences

Mon, 04 Aug 2025 23:00:00 +0100

June has been packed with interesting haematology conferences so the editorial team behind The Lancet Haematology have gathered to share their thoughts and reflect on their experiences at the European Hematology Association, International Conference on Malignant Lymphoma, and International Society on Thrombosis and Haemostasis meetings.

Read our conference round-ups here:

EHA: https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(25)00206-6/fulltext?dgcid=buzzsprout_icw_podcast_August_25_lanhae

ICML: https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(25)00207-8/fulltext?dgcid=buzzsprout_icw_podcast_August_25_lanhae

ISTH: https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(25)00209-1/fulltext?dgcid=buzzsprout_icw_podcast_August_25_lanhae

Paolo Strati on off-the-shelf induced pluripotent stem-cell-derived natural killer-cell therapy for patients with relapsed or refractory B-cell lymphoma

Tue, 01 Jul 2025 23:00:00 +0100

Associate Professor Paolo Strati (Department of Lymphoma and Myeloma, and Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA) joins us to discuss the results of a multicentre, open-label, phase 1 clinical trial of off-the-shelf induced pluripotent stem-cell-derived natural killer-cell therapy for patients with relapsed or refractory B-cell lymphoma.

Read the full article:

https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(25)00142-5/fulltext?dgcid=buzzsprout_icw_podcast_July_25_lanhae

A panel of the authors on our Adverse Events Series on adverse event reporting in haematological malignancies

Fri, 13 Jun 2025 12:00:00 +0100

With a growing number of treatment options for blood cancers, understanding the side effects from these treatments and how they affect patients is becoming ever more important. Join a panel of authors from The Lancet Haematology's latest series on Adverse Event reporting to discuss how we can improve clinical trial design and analysis, and translate this data to meaningful, patient-centric care.

Read the full series here:
https://www.thelancet.com/series-do/adverse-events-in-haematology-oncology?dgcid=buzzsprout_icw_podcast_13-06-25_lanhaeadverseevents25_lanhae

Michael Northend on early rituximab monotherapy versus watchful waiting for advanced stage, asymptomatic, low tumour burden follicular lymphoma

Mon, 28 Apr 2025 23:00:00 +0100

Dr Michael Northend (University College London Hospitals NHS Foundation Trust, and Cancer Research UK & UCL Cancer Trials Centre, London, UK) joins us to discuss the long-term results of a randomised, phase 3 trial on early rituximab monotherapy versus watchful waiting for advanced stage, asymptomatic, low tumour burden follicular lymphoma.

Read the full article:

https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(25)00034-1/fulltext?dgcid=buzzsprout_icw_podcast_28-04-25_lanhae

Joanne Verweij and Romy Pothof on fetal and neonatal alloimmune thrombocytopenia

Mon, 31 Mar 2025 23:00:00 +0100

Dr Romy Pothof and Prof Joanne Verweij join us to discuss their development of an international consensus on the diagnosis and treatment of fetal and neonatal alloimmune thrombocytopenia.

Read the full article:

https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(25)00029-8/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanhae

Helene Schoemans, Elke Stienissen, and Kathy Goris on a consulting a patient advisory board to understand unmet needs of patients with GVHD in Europe

Mon, 03 Mar 2025 23:00:00 +0000

Prof Helene Schoemans, Elke Stienissen, and Kathy Goris join us to discuss the importance of consulting a patient advisory board to understand unmet needs of patients with GVHD in Europe.

Dawn Swan on air pollution and venous thromboembolism

Wed, 29 Jan 2025 16:00:00 +0000

Dr Dawn Swan joins us to discuss current knowledge and future perspectives on the possible association between air pollution and venous thromboembolism.

Read the full article:
https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(24)00291-6/fulltext?dgcid=buzzsprout_icw_podcast_general_lanhae

Leslie Skeith on low-dose aspirin for postpartum venous thromboembolism prophylaxis

Thu, 16 Jan 2025 23:00:00 +0000

Dr Leslie Skeith joins us to discuss the PARTUM pilot trial, comparing low-dose aspirin versus placebo in postpartum venous thromboembolism.

Read the full article:
https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(24)00338-7/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanhae

Neema Mayor and Caitlin Farrow on impact of patient ethnicity on haematopoeietic cell transplantation outcome in the United Kingdom

Tue, 03 Dec 2024 23:00:00 +0000

Dr Neema Mayor and Dr Caitlin Farrow from the Anthony Nolan Research Institute join us to discuss the findings of their study on the impact of patient ethnicity on haematopoietic cell transplantation outcomes in the United Kingdom.

Read the full article:
https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(24)00312-0/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanhae

Lancet Haematology 10 year anniversary - meet the editors

Wed, 02 Oct 2024 11:00:00 +0100

In a special 10 year anniversary podcast, Lan-Lan Smith, Yaiza del Pozo Martin, and Emma Cookson, the editorial team behind The Lancet Haematology, reflect on the last decade and give some insights into the editorial processes at The Lancet Group.

Read our Editorial:
https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(24)00289-8/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanhae

Matteo Della Porta on the phase 3 COMMANDS trial examining luspatercept versus epoetin alfa in patients with lower-risk myleodysplastic syndrome

Thu, 22 Aug 2024 23:00:00 +0100

Professor Matteo Giovanni Della Porta joins us to discuss the primary analysis of the phase 3 COMMANDS trial comparing luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndrome patients.

Kim Linton on follicular lymphoma

Wed, 07 Aug 2024 14:00:00 +0100

Dr Kim Linton joins us to discuss the EPCORE NHL-1 trial testing monotherapy with the bispecific antibody epcoritamab for patients with relapsed or refractory follicular lymphoma.

Read the full article:
https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(24)00166-2?dgcid=buzzsprout_tlv_podcast_generic_lanhae

Judy Truong on ferritin reference levels and iron deficiency

Mon, 05 Aug 2024 15:00:00 +0100

Dr Judy Truong join us to discuss ferritin reference intervals and how adoption of evidence-based ferritin clinical decision limits can help clinicians detect and treat iron deficiency, minimising propagation of related health inequity and social injustice in medicine.

Read the full article:
https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(24)00103-0?dgcid=buzzsprout_tlv_podcast_generic_lanhae

Johannes Schetelig on remission induction versus immediate allogeneic HSCT for patients with AML

Tue, 16 Jul 2024 09:00:00 +0100

Professor Johannes Schetelig joins us to discuss the results of the ASAP phase 3 trial comparing remission induction with immediate allogeneic haematopoietic stem cell transplantation for patients with relapsed or poor responsive acute myeloid leukaemia.

Read the full article:
https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(24)00065-6/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanhae

Banu Aygun on sickle cell anaemia

Thu, 23 May 2024 23:00:00 +0100

Professor Banu Aygun joins us to discuss the REACH trial testing hydroxyurea dose optimisation for children with sickle cell anaemia in sub-Saharan Africa.

Read the full article:
https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(24)00078-4?dgcid=buzzsprout_icw_podcast_generic_lanhae

Sabine Braat and Katherine Fielding on haemoglobin thresholds to define anaemia

Fri, 01 Mar 2024 13:00:00 +0000

Dr Sabine Braat and Dr Katherine Fielding join us to discuss their study presenting new haemoglobin thresholds for defining anaemia.

Read the full article:
https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(24)00030-9/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanhae

Elisabeth Schorb on the MARTA phase 2 trial

Thu, 29 Feb 2024 12:00:00 +0000

Doctor Elisabeth Schorb joins us to discuss the MARTA phase 2 trial, treating older, fit patients with primary diffuse large B-cell CNS lymphoma with high-dose chemotherapy and autologous stem-cell transplantation.

Read the full article:
https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(23)00371-X/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanhae

Stephan Ehl on paediatric autoimmune lymphoproliferative immunodeficiencies

Wed, 31 Jan 2024 23:00:00 +0000

Professor Stephan Ehl joins us to discuss a prospective observational study on paediatric autoimmune lymphoproliferative immunodeficiencies.

Read the full article:
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00638-1/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanonc

Dr Sarah O'Brien on the PREVAPIX-ALL trial

Wed, 20 Dec 2023 15:00:00 +0000

Dr Sarah O'Brien joins Lan-Lan Smith to discuss results of the phase 3 PREVAPIX-ALL trial, which compares direct oral anticoagulant apixaban to low-molecular-weight-heparin for the prevention of venous thromboembolism in children with newly diagnosed acute lymphoblastic leukaemia or lymphoma.

Read the full article:
https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(23)00314-9/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanhae

Enrico Lopriore on haemolytic disease of the fetus and newborn

Wed, 29 Nov 2023 14:00:00 +0000

Professor Enrico Lopriore joins us to discuss a trial testing darbepoetin alfa to prevent postnatal anaemia in infants with haemolytic disease of the fetus and newborn.

Read the full article:
https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(23)00285-5/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanhae

Meletios Dimopoulos on relapsed and refractory multiple myeloma

Tue, 03 Oct 2023 11:00:00 +0100

Professor Meletios Dimopoulos joins us to discuss two trials for patients with relapsed and refractory multiple myeloma - the first report of the DREAMM-3 phase 3 and long-term follow-up of the APOLLO phase 3 trial.

Read the full article:
https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(23)00243-0/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanhae

Eric Ohuma on haemoglobin concentrations and neonatal outcomes

Tue, 29 Aug 2023 23:00:00 +0100

Dr Eric Ohuma joins us to tell us about a study recently published in The Lancet Haematology on the association between maternal haemoglobin concentrations and maternal and neonatal outcomes.

Read the full article:
https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(23)00170-9/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanhae

Margaret Ragni on tranexamic acid to treat heavy menstrual bleeding

Mon, 31 Jul 2023 23:00:00 +0100

Professor Margaret Ragni joins us to discuss the VWDMin study, published in The Lancet Haematology. In this phase 3, randomised, crossover trial, recombinant von Willebrand factor and tranexamic acid are used to treat heavy menstrual bleeding in patients with mild and moderate von Willebrand disease in the USA.

Read the full article:
https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(23)00119-9/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanhae

Oreofe Odejide and Thomas Kuczmarski on mental health and lymphoma

Mon, 03 Jul 2023 23:00:00 +0100

Dr Odejide and Dr Kuczmarski tell us about a study recently published in The Lancet Haematology on the effect of pre-existing mental health conditions on survival in patients with diffuse large B-cell lymphoma.

Read the full article:
https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(23)00094-7/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanhae

Alok Srivastava on fitusiran for patients with haemophilia A and B

Wed, 29 Mar 2023 09:00:00 +0100

Professor Alok Srivastava tells us about two clinical trials being published in The Lancet and The Lancet Haematology on a new siRNA therapy called fitusiran for patients with haemophilia A and B.

Read the two trials:
Efficacy and safety of fitusiran prophylaxis in people with haemophilia A or haemophilia B with inhibitors (ATLAS-INH)
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)00284-2/fulltext?dgcid=buzzsprout_icw_podcast_buzzsprout_general

Fitusiran prophylaxis in people with severe haemophilia A or haemophilia B without inhibitors (ATLAS-A/B)
https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(23)00037-6/fulltext?dgcid=buzzsprout_icw_podcast_buzzsprout_general

Emmanuela E Ambrose on stroke prevention in children with sickle cell disease

Thu, 02 Mar 2023 14:00:00 +0000

Dr Emmanuela E Ambrose tells us about the SPHERE trial on hydroxyurea dose escalation for primary stroke prevention in children with sickle cell disease in Tanzania

Read the full article:
Hydroxyurea with dose escalation for primary stroke risk reduction in children with sickle cell anaemia in Tanzania (SPHERE)

Sumit Gupta on racial and ethnic disparities in leukaemia survival outcomes

Mon, 30 Jan 2023 23:00:00 +0000

Dr Sumit Gupta discusses how racial and ethnic disparities affect survival outcomes of children and young adults with acute lymphocytic leukaemia.

Read the full article:
Racial and ethnic disparities in childhood and young adult acute lymphocytic leukaemia

Xiao-Jun Huang on cellular therapy in China

Mon, 28 Nov 2022 23:00:00 +0000

Professor Xiao-Jun Huang discusses this Lancet Haematology series on Cellular Therapy in China, covering the history, current research challenges, and future of HSCT and CAR T-cell therapies in China.

Read the Series papers:
Cellular therapy in China

Glenn Pierce on haemophilia care in LMICs

Tue, 30 Aug 2022 23:00:00 +0100

Dr Glenn Pierce discusses the World Federation of Hemophilia’s Humanitarian Aid Program which provides access to haemophilia care in low-income and lower-middle-income countries.

Read the full Review:
Achieving access to haemophilia care in low-income and lower-middle-income countries

Amy DeZern on the link between myelodysplastic syndrome and autoimmune disorders

Thu, 30 Jun 2022 11:00:00 +0100

Dr Amy DeZern discusses the link between myelodysplastic syndrome and autoimmune disorders and the need for a multidisciplinary approach for the treatment of patients who have both.

Read the full article:
Myelodysplastic syndrome and autoimmune disorders: two sides of the same coin?

Nicholas Crombie and Gavin Perkins on resuscitation with blood products compared with saline

Mon, 07 Mar 2022 20:00:00 +0000

Dr Nicholas Crombie and Professor Gavin Perkins discuss their randomised phase 3 trial in which they investigated resuscitation with blood products compared with saline in patients with trauma-related haemorrhagic shock receiving prehospital care.

Fredrik Schjesvold on OCEAN phase 3

Mon, 31 Jan 2022 23:00:00 +0000

Dr Fredrik Schjesvold discusses the results of the OCEAN phase 3 trial testing melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide.

Read the full article:
Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN)

Jacob D Soumerai and Andrew D Zelenetz on the BOVen regimen for previously untreated patients with chronic lymphocytic leukaemia

Thu, 25 Nov 2021 11:00:00 +0000

Dr Jacob D Soumerai and Prof Andrew D Zelenetz discuss their phase 2 trial of the BOVen regimen and MRD-driven treatment discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma.

Read the full article:
https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(21)00307-0/fulltext

Raul Cordoba on haematological malignancies in older people

Wed, 03 Nov 2021 23:00:00 +0000

Dr Raul Cordoba discusses the joint Series between The Lancet Healthy Longevity and The Lancet Haematology on haematological malignancies in older people.

Read the full article:
A comprehensive approach to therapy of haematological malignancies in older patients

Obiageli Nnodu and Dennis Chao on child mortality from sickle cell disease in Nigeria

Tue, 21 Sep 2021 15:00:00 +0100

Professor Obiageli Nnodu and Dr Dennis Chao join acting Deputy Editor Emma Cookson to talk about their new study describing modelling of child mortality as a result of sickle cell disease in Nigeria.

Read the full article:
https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(21)00191-5/fulltext

Zuguo Mei and Gary Brittenham on iron deficiency

Tue, 27 Jul 2021 23:00:00 +0100

Senior Assistant Editor Ben Burwood speaks with Dr Zuguo Mei (Division of Nutrition, Physical Activity, and Obesity, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, GA, USA) and Dr Gary M Brittenham (Department of Pediatrics, College of Physicians and Surgeons, Columbia University, New York, NY, USA) about their work defining physiologically based serum ferritin thresholds for iron deficiency.

Read the full article:
https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(21)00168-X/fulltext

Eugenia Trigoso Arjona (in English) on nursing and haematological care

Tue, 11 May 2021 23:00:00 +0100

To mark International Nurses Day, Eugenia Trigoso Arjona, nurse coordinator at Hospital La Fe (Valencia, Spain) and chair of the European Society for Blood and Marrow Transplantation Nurses Global Education Committee, joins acting Editor-in-Chief Yaiza del Pozo Martin to discuss how nurses can reshape the future of haematological care.

Eugenia Trigoso Arjona (in Spanish) on nursing and haematological care

Tue, 11 May 2021 23:00:00 +0100

Para el Día International de la Enfermera, Eugenia Trigoso Arjona, enfermera coordinadora en el Hospital La Fe (Valencia, España) y presidenta del comité de educación de la European Society for Blood and Marrow Transplantation Nurses hablo con la Editora Yaiza del Pozo Martin sobre como las enfermeras pueden remodelar el futuro de la hematología.

Nada Hamad on inclusion and diversity in haematology

Tue, 23 Feb 2021 23:00:00 +0000

A/Prof Nada Hamad (St Vincent’s hospital, Sydney, Australia) joins Editor-in-Chief Dr Lan-Lan Smith to discuss inclusion and diversity in haematology-oncology and transplantation.

Dr Judith Boer on lymphoblastic leukaemia in children

Tue, 22 Dec 2020 23:00:00 +0000

Editor-in-Chief, Dr Lan-Lan Smith, speaks with Dr Judith Boer (Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands) about outcome of ABL-class acute lymphoblastic leukaemia in children in the pre-tyrosine kinase inhibitor era.

Read the full article:
https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(20)30353-7/fulltext